Sutro Biopharma (STRO) — Strategic Asset Allocation Index
Sutro Biopharma (STRO) has a Strategic Asset Allocation Index of 31.5% as of June 2023. Strategic assets (PP&E of $48.77 Million plus long-term investments of $-) total $48.77 Million, measured against net assets of $154.72 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Sutro Biopharma Strategic Asset Allocation Index (2018–2022)
This chart shows how Sutro Biopharma's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of June 2023, the index stands at 31.5%, representing strategic assets of $48.77 Million against net assets of $154.72 Million USD. Explore Sutro Biopharma cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Sutro Biopharma (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Sutro Biopharma from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Sutro Biopharma.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 38.3% | $83.08 Million | $51.06 Million | $32.02 Million | $217.05 Million | ▼ -9.4 pp |
| 2021 | 47.7% | $120.37 Million | $51.59 Million | $68.78 Million | $252.56 Million | ▲ +43.8 pp |
| 2020 | 3.9% | $12.94 Million | $12.94 Million | $0.00 | $332.05 Million | ▼ -21.9 pp |
| 2019 | 25.8% | $25.24 Million | $9.63 Million | $15.61 Million | $97.79 Million | ▲ +17.5 pp |
| 2018 | 8.3% | $10.93 Million | $10.93 Million | $- | $131.54 Million | — |